These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 1489855)

  • 1. Significance of bone alkaline phosphatase, CA 15-3 and CEA in the detection of bone metastases during the follow-up of patients suffering from breast carcinoma.
    Stieber P; Nagel D; Ritzke C; Rössler N; Kirsch CM; Eiermann W; Fateh-Moghadam A
    Eur J Clin Chem Clin Biochem; 1992 Dec; 30(12):809-14. PubMed ID: 1489855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Skeletal alkaline phosphatase as a serum marker of bone metastases in the follow-up of patients with breast cancer.
    Reale MG; Santini D; Marchei GG; Manna A; Del Nero A; Bianco V; Marchei P; Frati L
    Int J Biol Markers; 1995; 10(1):42-6. PubMed ID: 7629426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison between CEA, TPA, CA 15/3 and hydroxyproline, alkaline phosphatase, whole body retention of 99mTc MDP in the follow-up of bone metastases in breast cancer.
    Francini G; Montagnani M; Petrioli R; Paffetti P; Marsili S; Leone V
    Int J Biol Markers; 1990; 5(2):65-72. PubMed ID: 2283479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A profile of serum CA 15-3, carcinoembryonic antigen, alkaline phosphatase, and gamma-glutamyl transferase levels in patients with breast cancer.
    Buamah PK; Bent DJ; Bodger WA; Skillen AW
    J Surg Oncol; 1993 Jun; 53(2):84-7. PubMed ID: 8099132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.
    Nicolini A; Tartarelli G; Carpi A; Metelli MR; Ferrari P; Anselmi L; Conte M; Berti P; Miccoli P
    BMC Cancer; 2006 Nov; 6():269. PubMed ID: 17116247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isoenzymes of alkaline and acid phosphatases as bones metastasis marker in breast cancer patients.
    Desoize B; Veiler V; Pourny C; Comoe L; Jardillier JC
    Anticancer Res; 1989; 9(4):1105-9. PubMed ID: 2817792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel method for monitoring high-risk breast cancer with tumor markers: CA 15.3 compared to CEA and TPA.
    Sölétormos G; Nielsen D; Schiøler V; Skovsgaard T; Winkel P; Mouridsen HT; Dombernowsky P
    Ann Oncol; 1993 Dec; 4(10):861-9. PubMed ID: 8117606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expressiveness of Bone Markers in Breast Cancer with Bone Metastases.
    Zulauf N; Brüggmann D; Groneberg D; Oremek GM
    Oncology; 2019; 97(4):236-244. PubMed ID: 31412345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Procollagen-I, collagen telopeptide I, CEA, CA 15-3 as compared to bone scintigraphy in patients with breast cancer].
    Zissimopoulos A; Petrakis G; Stellos K; Baziotis N
    Hell J Nucl Med; 2006; 9(1):60-4. PubMed ID: 16617400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma acid and alkaline phosphatase in patients with breast cancer.
    Nguyen M; Bonneterre J; Hecquet B; Desoize B; Demaille A
    Anticancer Res; 1991; 11(2):831-3. PubMed ID: 2064338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of bone scintigraphy with serum tumor markers of CA 15-3 and carcinoembryonic antigen in patients with breast carcinoma.
    Gedik GK; Kiratli PO; Tascioglu B; Aras T
    Saudi Med J; 2006 Mar; 27(3):317-22. PubMed ID: 16532090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between bone scintigraphy and tumor markers in patients with breast carcinoma.
    Begić A; Kucukalić-Selimović E; Obralić N; Durić O; Lacević N; Skopljak A
    Bosn J Basic Med Sci; 2006 Feb; 6(1):75-7. PubMed ID: 16533185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum CA-15.3 and CEA patterns in postsurgical follow-up, and in monitoring clinical course of metastatic cancer in patients with breast carcinoma.
    al-Jarallah MA; Behbehani AE; el-Nass SA; Temim L; Ebraheem AK; Ali MA; Szymendera JJ
    Eur J Surg Oncol; 1993 Feb; 19(1):74-9. PubMed ID: 8436243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alkaline phosphatase isoenzymes in detection and follow up of breast cancer metastases.
    Ritzke C; Stieber P; Untch M; Nagel D; Eiermann W; Fateh-Moghadam A
    Anticancer Res; 1998; 18(2B):1243-9. PubMed ID: 9615795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
    Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
    Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The value of the tumor marker CA 15-3 in diagnosing and monitoring breast cancer. A comparative study with carcinoembryonic antigen.
    Safi F; Kohler I; Röttinger E; Beger H
    Cancer; 1991 Aug; 68(3):574-82. PubMed ID: 2065278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone alkaline phosphatase isoenzyme and urinary hydroxyproline in healthy subjects, patients with osteolytic metastases, and patients with primary hyperparathyroidism.
    Stĕpán JJ; Mikulecký M; Bek V; Broulík P; Pacovský V
    Neoplasma; 1989; 36(4):495-501. PubMed ID: 2770935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of bone and liver metastases from breast cancer by measurement of plasma alkaline phosphatase isoenzyme activity.
    Mayne PD; Thakrar S; Rosalki SB; Foo AY; Parbhoo S
    J Clin Pathol; 1987 Apr; 40(4):398-403. PubMed ID: 3584482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aminoterminal propeptide of type I collagen and bone alkaline phosphatase in the study of bone metastases associated with prostatic carcinoma.
    Díaz-Martín MA; Traba ML; De La Piedra C; Guerrero R; Méndez-Dávila C; De La Peña EG
    Scand J Clin Lab Invest; 1999 Apr; 59(2):125-32. PubMed ID: 10353326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CA 15-3 and bone scintigraphy in the follow-up of breast cancer.
    Younsi N; Montravers F; Philippe C; Seddiki M; Uzan S; Izrael V; Talbot JN
    Int J Biol Markers; 1997; 12(4):154-7. PubMed ID: 9582604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.